Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VKTX Stock Price Chart Interactive Chart >
VKTX Price/Volume Stats
| Current price | $11.65 | 52-week high | $11.98 |
| Prev. close | $11.83 | 52-week low | $2.02 |
| Day low | $10.95 | Volume | 2,933,632 |
| Day high | $11.92 | Avg. volume | 2,005,018 |
| 50-day MA | $10.08 | Dividend yield | N/A |
| 200-day MA | $5.34 | Market Cap | 913.58M |
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Latest VKTX News From Around the Web
Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. Indeed, Viking Therapeutics... |
Viking Therapeutics to Participate at Upcoming Investor ConferencesViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. |
2 Surging Healthcare Stocks That Are Still Worth BuyingMadrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) bucked this downward trend in a big way. Here's why these two surging healthcare stocks are still worth buying right now. Madrigal's shares have been charging higher of late in response to a positive late-stage readout for its lead product candidate, resmetirom, in nonalcoholic steatohepatitis (NASH). |
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call TranscriptViking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Welcome to the Viking Therapeutics Fourth Quarter and Full-year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. As a reminder, this conference call […] |
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments. |
VKTX Price Returns
| 1-mo | 3.19% |
| 3-mo | 62.03% |
| 6-mo | 300.34% |
| 1-year | 245.70% |
| 3-year | 169.68% |
| 5-year | 118.57% |
| YTD | 23.94% |
| 2022 | 104.35% |
| 2021 | -18.29% |
| 2020 | -29.80% |
| 2019 | 4.84% |
| 2018 | 88.42% |
Loading social stream, please wait...